{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Systemic+Sclerosis+%28SSc%29&page=2",
    "query": {
      "condition": "Systemic Sclerosis (SSc)",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Systemic+Sclerosis+%28SSc%29&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T09:47:47.063Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05000216",
      "title": "COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rheumatoid Arthritis (RA)",
        "Systemic Lupus Erythematosus (SLE)",
        "Pemphigus Vulgaris",
        "Multiple Sclerosis (MS)",
        "Systemic Sclerosis (SSc)",
        "Pediatric SLE",
        "Juvenile Idiopathic Arthritis (JIA)",
        "Juvenile Dermatomyositis (JDM)",
        "Pediatric-Onset Multiple Sclerosis (POMS)"
      ],
      "interventions": [
        {
          "name": "Moderna mRNA-1273",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BNT162b2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ad26.COV2.S",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Continue IS (MMF or MPA)",
          "type": "DRUG"
        },
        {
          "name": "Continue IS (MTX)",
          "type": "DRUG"
        },
        {
          "name": "Continue IS (B cell depletion therapy)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Monovalent [B.1.351] CoV2 preS dTM-AS03",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Withhold IS (MMF or MPA)",
          "type": "DRUG"
        },
        {
          "name": "Withhold IS (MTX)",
          "type": "DRUG"
        },
        {
          "name": "Withhold IS (B cell depletion therapy)",
          "type": "DRUG"
        },
        {
          "name": "Moderna mRNA-1273, Bivalent",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BNT162b2, Bivalent",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 258,
      "start_date": "2021-08-13",
      "completion_date": "2024-03-28",
      "has_results": true,
      "last_update_posted_date": "2025-08-22",
      "last_synced_at": "2026-05-22T09:47:47.063Z",
      "location_count": 29,
      "location_summary": "Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 18 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05000216"
    },
    {
      "nct_id": "NCT01072669",
      "title": "Efficacy of Ambrisentan in Limited Scleroderma Patients in Improving Blood Flow to Hands or Feet",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Ischemia"
      ],
      "interventions": [
        {
          "name": "ambrisentan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Soumya Chatterjee",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 20,
      "start_date": "2010-02",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2013-05-03",
      "last_synced_at": "2026-05-22T09:47:47.063Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01072669"
    },
    {
      "nct_id": "NCT02530996",
      "title": "Systemic Sclerosis (SSc) Vasculopathy: Improved Clinical Monitoring and Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Rheumatologic Disease"
      ],
      "interventions": [
        {
          "name": "BH4",
          "type": "DRUG"
        },
        {
          "name": "Vasculopathy assessment",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "95 Years",
        "sex": "ALL",
        "summary": "18 Years to 95 Years"
      },
      "enrollment_count": 12,
      "start_date": "2016-01-01",
      "completion_date": "2019-12-31",
      "has_results": true,
      "last_update_posted_date": "2021-04-05",
      "last_synced_at": "2026-05-22T09:47:47.063Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02530996"
    },
    {
      "nct_id": "NCT02370693",
      "title": "Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Diseases, Interstitial",
        "Systemic Sclerosis",
        "Scleroderma"
      ],
      "interventions": [
        {
          "name": "Bortezomib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate mofetil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2016-03",
      "completion_date": "2020-01-01",
      "has_results": true,
      "last_update_posted_date": "2021-08-25",
      "last_synced_at": "2026-05-22T09:47:47.063Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02370693"
    },
    {
      "nct_id": "NCT07085104",
      "title": "A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Systemic Lupus Erythematosus (With and Without Nephritis)",
        "Idiopathic Inflammatory Myopathy",
        "Systemic Sclerosis"
      ],
      "interventions": [
        {
          "name": "ALLO-329",
          "type": "GENETIC"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "DRUG"
      ],
      "sponsor": "Allogene Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "18 Years to 69 Years"
      },
      "enrollment_count": 66,
      "start_date": "2025-11-13",
      "completion_date": "2032-10",
      "has_results": false,
      "last_update_posted_date": "2026-04-07",
      "last_synced_at": "2026-05-22T09:47:47.063Z",
      "location_count": 12,
      "location_summary": "Phoenix, Arizona • Aurora, Colorado • Jacksonville, Florida + 9 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07085104"
    },
    {
      "nct_id": "NCT00684255",
      "title": "Reduced Intensity Transplant in Medically Refractory Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Systemic Lupus Erythematosus",
        "Systemic Sclerosis"
      ],
      "interventions": [
        {
          "name": "Reduced Intensity Allogeneic Transplant",
          "type": "PROCEDURE"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Campath",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "New York Medical College",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "7 Years to 50 Years"
      },
      "enrollment_count": 1,
      "start_date": "2007-08",
      "completion_date": "2008-07",
      "has_results": true,
      "last_update_posted_date": "2014-04-01",
      "last_synced_at": "2026-05-22T09:47:47.063Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00684255"
    },
    {
      "nct_id": "NCT03313180",
      "title": "A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung Fibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lung Diseases, Interstitial"
      ],
      "interventions": [
        {
          "name": "Nintedanib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 444,
      "start_date": "2017-11-27",
      "completion_date": "2023-01-25",
      "has_results": true,
      "last_update_posted_date": "2024-02-20",
      "last_synced_at": "2026-05-22T09:47:47.063Z",
      "location_count": 39,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Sacramento, California + 31 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03313180"
    },
    {
      "nct_id": "NCT01086540",
      "title": "Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Systemic Sclerosis-Associated PAH"
      ],
      "interventions": [
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "CMRI",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "prednisone",
          "type": "DRUG"
        },
        {
          "name": "methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "diphenhydramine",
          "type": "DRUG"
        },
        {
          "name": "acetaminophen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "DIAGNOSTIC_TEST",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 57,
      "start_date": "2011-06-24",
      "completion_date": "2019-12-15",
      "has_results": true,
      "last_update_posted_date": "2023-02-21",
      "last_synced_at": "2026-05-22T09:47:47.063Z",
      "location_count": 17,
      "location_summary": "Stanford, California • Aurora, Colorado • Iowa City, Iowa + 13 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01086540"
    },
    {
      "nct_id": "NCT06195072",
      "title": "Platform Clinical Study for Conquering Scleroderma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Interstitial Lung Disease Due to Systemic Disease",
        "Scleroderma"
      ],
      "interventions": [
        {
          "name": "Amlitelimab",
          "type": "DRUG"
        },
        {
          "name": "BI 1015550 (Nerandomilast)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Scleroderma Research Foundation, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 400,
      "start_date": "2024-04-15",
      "completion_date": "2026-11",
      "has_results": false,
      "last_update_posted_date": "2026-02-04",
      "last_synced_at": "2026-05-22T09:47:47.063Z",
      "location_count": 34,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 23 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06195072"
    },
    {
      "nct_id": "NCT05270668",
      "title": "Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Cutaneous Systemic Sclerosis",
        "Interstitial Lung Disease"
      ],
      "interventions": [
        {
          "name": "Tulisokibart",
          "type": "DRUG"
        },
        {
          "name": "Companion diagnostic ( CDx)",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 154,
      "start_date": "2022-03-29",
      "completion_date": "2029-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-18",
      "last_synced_at": "2026-05-22T09:47:47.063Z",
      "location_count": 20,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 14 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05270668"
    }
  ]
}